Apposite Capital

Kelso Pharma is an innovative pharmaceutical manufacturing company focused on improving patient outcomes through the development and distribution of branded medications. By prioritizing cost-effectiveness, Kelso Pharma aims to meet the diverse needs of patients, helping them recover from various illnesses. The firm is dedicated to enhancing the healthcare market by providing high-quality medications designed to benefit patients and support their health and well-being.

Mirada Medical Limited is a developer of medical imaging software applications focused on enhancing patient outcomes in various medical fields, including radiology, molecular imaging, and radiation oncology. Founded in 1999 and headquartered in Oxford, United Kingdom, with an additional office in Denver, Colorado, the company provides innovative solutions such as Mirada XD, an enterprise software for nuclear medicine and image fusion; DLCExpert, which offers automated organ-at-risk contouring services; and Mirada IM, designed to support interventional medicine and optimize radioembolization therapy. Mirada's products are utilized in hospitals, imaging centers, and cancer centers globally, facilitating multidisciplinary meetings and enabling healthcare professionals to effectively diagnose, manage, and treat cancer and other diseases through advanced technology. The company distributes its software through direct sales and partnerships with distributors.

CrestOptics is a company specializing in the development and manufacture of advanced systems for fluorescence microscopy. Based in Rome, Italy, it leverages the expertise of its team, which has extensive experience in scientific research, industrial design, and electrooptical systems. The company focuses on creating state-of-the-art instruments that enhance the capabilities of researchers and industries engaged in fluorescence microscopy and spectroscopy. CrestOptics is known for its commitment to innovation, working on collaborative research projects with renowned institutions, such as CNR – FISBAT, to advance technologies for live cell imaging and laser-activated experiments. By combining optical and electrooptical technology with tailored services, CrestOptics provides solutions that improve sensitivity, image quality, and clarity, meeting the evolving demands of the scientific community.

i2a SA is a diagnostic and medical informatics company based in Montpellier, France, founded in 1988 by three engineers from Polytechnique. The company specializes in manufacturing and marketing instruments, software, and reagents for microbiology laboratories and infection prevention services, addressing the comprehensive needs of these facilities. i2a is known for its SirScan products, which include automatic readers for disc diffusion susceptibility tests, as well as its SIR software designed for monitoring susceptibility tests and epidemiological data. The company also provides a variety of bacteriology reagents, such as rapid susceptibility testing media and antibiotic discs. With a strong presence in France, where it supplies around 75% of hospitals, i2a is recognized as a key partner in the field of bacteriology. The company combines expertise in microbiology, robotics, and computer science, continuously adapting its products to user needs and focusing on future innovations and international expansion.

1Med is a comprehensive contract research organization (CRO) that specializes in providing a wide range of clinical research services and solutions tailored to meet the needs of clinical trials. The company offers expertise in regulatory strategy, clinical trial management, and quality assurance, supporting clients throughout the product lifecycle from initial design and development to certification. By delivering robust regulatory, medical, preclinical, and clinical services, 1Med enables businesses to maintain essential internal competencies and effectively achieve their objectives in the complex landscape of clinical research.

Emblation is a company specializing in medical research and product development, focusing on the advancement of microwave technology for healthcare applications. The firm designs, manufactures, and commercializes innovative microwave-based solutions aimed at treating various skin conditions, as well as providing services in oncology, dermatology, and podiatry. Emblation’s products leverage the precise destruction of tissue and the immune activation effects associated with microwave treatments, supporting health professionals in delivering effective care to patients with conditions such as HPV infections and other dermatological issues. The company is dedicated to enhancing treatment methodologies within the medical field through its next-generation technologies.

Archway Dental Practice Limited is a dental care provider located in Dursley, United Kingdom, with an operational history dating back to 1996. Catering primarily to private patients, the practice offers a range of dental services, including surgeries, diagnostic procedures, and preventative care. With a commitment to delivering high-quality dentistry, Archway Dental Practice serves the local communities of Dursley and Stroud. As of September 2019, the practice operates as a subsidiary of Riverdale Healthcare Limited, enhancing its capacity to provide comprehensive dental care.

Mirada Medical Limited is a developer of medical imaging software applications focused on enhancing patient outcomes in various medical fields, including radiology, molecular imaging, and radiation oncology. Founded in 1999 and headquartered in Oxford, United Kingdom, with an additional office in Denver, Colorado, the company provides innovative solutions such as Mirada XD, an enterprise software for nuclear medicine and image fusion; DLCExpert, which offers automated organ-at-risk contouring services; and Mirada IM, designed to support interventional medicine and optimize radioembolization therapy. Mirada's products are utilized in hospitals, imaging centers, and cancer centers globally, facilitating multidisciplinary meetings and enabling healthcare professionals to effectively diagnose, manage, and treat cancer and other diseases through advanced technology. The company distributes its software through direct sales and partnerships with distributors.

Riverdale Healthcare is a dentistry investment group focused on delivering high-quality and ethical dental care through a network of clinics. The organization provides a wide range of dental services, including teeth straightening, replacement, restoration, smile enhancement, and dental implants. By offering comprehensive oral healthcare solutions, Riverdale Healthcare aims to ensure that patients receive tailored dental advice and effective treatments, positioning itself as a trusted provider in the dental industry.

Prime Health Diagnostics is a healthcare company based in Weybridge, United Kingdom, established in 2010. It operates a facility that integrates diagnostic, treatment, and fitness services under one roof. The company provides a range of medical and diagnostics services, including consultant clinics, private GP consultations, advanced 3T MRI scans, ultrasound, and X-ray imaging. Additionally, Prime Health Diagnostics offers therapy and fitness services such as physiotherapy, osteopathy, personal training, Pilates, nutritional therapy, podiatry, sports massage, performance coaching, and complementary therapy.

OrthoD Group, now known as Summit Medical Group Limited, is a manufacturer and distributor of medical products specializing in joint reconstruction and sports medicine. The company produces a range of medical devices, including surgical products, sports medicine implants, and accessories for infection control. Its offerings include reconstruction devices, autologous blood transfusion systems, bone cement and delivery systems, exsanguinating sterile tourniquets, and wound drains. Founded in 1984 and based in Cheltenham, United Kingdom, the company also operates in France, serving various medical needs through its innovative products.

Swanton Care & Community specializes in providing residential and supported living services for adults with complex learning disabilities, mental health disorders, and acquired brain injuries. The company operates 24 care homes across East Anglia, the West Midlands, South West Wales, the North East, and Scotland, offering a total of 259 registered beds. In addition to residential care, Swanton has a growing supported living service in key localities. The organization employs approximately 780 staff members and generated revenues of £25 million in the most recent fiscal year. Swanton emphasizes collaboration with patients' families, healthcare professionals, and care teams to understand individual needs, focusing on enablement and promoting independence, allowing patients to take an active role in setting their own goals and outcomes.

NIMGenetics is a diagnostic center authorized by the Madrid Health Authority, specializing in high-resolution genomic systems for precise clinical diagnosis. The company employs advanced genomic and next-generation sequencing (NGS) microarray technologies to analyze genetic information, which aids in the diagnosis of various clinical disorders. Its focus spans multiple medical disciplines, including gynecology, neurology, pediatrics, and oncology. By providing reliable and accurate genetic diagnoses, NIMGenetics supports medical professionals in enhancing patient health outcomes for those affected by genetic diseases. The organization's scientifically accredited team is dedicated to advancing the field of medical genetics through innovative diagnostic solutions.

Enara Group specializes in delivering high-quality home care services in the UK, catering to individuals who need assistance due to illness, disability, or infirmity. The company offers a diverse range of care options, ensuring tailored support for its clients. Enara works with various funding sources, including local authorities, the National Health Service (NHS), and private pay agreements, allowing it to reach a broad demographic and provide essential services to those in need.

Complete Care is a healthcare service provider specializing in high acuity care for individuals with complex clinical needs across England and Wales. The company supports approximately 150 clients, offering rehabilitative care and assistance for conditions such as cerebral palsy, motor neuron diseases, and muscular dystrophy. With a workforce of around 650 personal care assistants, including registered nurses, Complete Care focuses on delivering personalized healthcare within the comfort of patients' homes, facilitating their recovery and improving their overall health. This approach not only enhances patient well-being but also complements existing domiciliary care operations in the region.

MiHomecare is a provider of social care services, offering a broad spectrum of assistance tailored to individuals' needs, enabling them to maintain independent living at home despite mobility or health challenges stemming from age, illness, disability, or infirmity. Their services encompass personal care, medication aid, meal preparation, light housework, live-in care, and complex care requirements.

Medical Imaging Partnership is a provider of radiology services established by UK Radiologists to deliver high-quality imaging services to both private and NHS patients. The organization aims to ensure fast access to expert-led services for patients and referrers alike. Its offerings include a range of fully managed clinical services such as MRI, CT, ultrasound, X-ray, dual-energy X-ray absorptiometry scans, and ultrasound-guided steroid injections. Medical Imaging Partnership is recognized for its commitment to excellence, providing reports from leading specialist Radiologists. Additionally, it is accredited by major private medical insurers and offers competitive self-pay pricing, making reliable health tests and checkups accessible to a broad audience.

Bird Rock Bio, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, with a research facility in Shanghai, China. The company specializes in the discovery and development of novel biologic therapeutics aimed at addressing immune-inflammatory conditions, including rheumatoid arthritis, metabolic diseases, fibrosis, and nonalcoholic steatohepatitis. Bird Rock Bio's technology focuses on creating highly selective monoclonal antibodies targeting specific members of the G-protein coupled receptor (GPCR) family, a class of proteins critical for therapeutic efficacy. Its lead product, RYI-008, is a potent monoclonal antibody targeting IL-6, a cytokine linked to inflammation and cancer. The company is dedicated to meeting the medical needs of patients in China while also aiming for global impact. Bird Rock Bio has a growing pipeline of therapeutic antibodies developed through proprietary technologies that ensure specificity and effectiveness in treatment.

Cancer Partners UK is a provider of cancer treatment services that operates a network of purpose-built cancer centres across the United Kingdom. Each centre is designed to address the specific needs of its local community and offers a range of services, including diagnostics, surgery, chemotherapy, radiotherapy, and palliative care. The company is committed to delivering high-quality, patient-focused care, ensuring that patients have prompt access to necessary diagnostic procedures and treatments from the moment they are referred by their GP. By offering comprehensive cancer care under one roof, Cancer Partners UK aims to enhance the overall patient experience and improve treatment outcomes.

Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.

Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.

Ulthera is an emerging medical technology company based in Mesa, Arizona, specializing in ultrasound-based devices for aesthetic and medical applications. The company focuses on noninvasive procedures aimed at skin rejuvenation and the treatment of underlying tissue, addressing a growing demand in the aesthetic market. Ulthera's flagship product, the Ulthera® System, features patented DeepSEE™ technology, which combines imaging and therapy capabilities to provide effective and safe results. Originally conceived from research into image-guided cancer therapy, Ulthera has evolved over seven years to meet the unique needs of the aesthetic industry, offering innovative solutions for both patients and practitioners.

Convergence Pharmaceuticals is an independent biotechnology company established in October 2010, following the acquisition of neuroscience clinical assets from GlaxoSmithKline. The company specializes in the development of novel analgesics, focusing on creating small molecule sodium channel blockers that are designed to effectively treat neuropathic pain. Convergence Pharmaceuticals is committed to developing differentiated clinical-stage compounds that target key points in chronic pain signaling by modulating specific ion channels. Its innovative approach aims to achieve commercially attractive efficacy, responder rates, and side effect profiles, positioning the company as a notable player in the analgesic market.

SureCalm Healthcare is dedicated to delivering high-quality homecare services for patients managing long-term chronic conditions. The company offers a comprehensive range of healthcare solutions tailored for home settings, specializing in stoma care and continence devices. Additionally, SureCalm provides home delivery services and personalized care options. Recently, the company has expanded its offerings to include an internet and mail order pharmacy, ensuring that clients have access to their medication needs along with professional advice.

Anaphore (formerly ImmunoNewCo) is developing a new class of protein therapeutics to address significant unmet medical needs for patients with serious or life-threatening diseases.

Bird Rock Bio, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, with a research facility in Shanghai, China. The company specializes in the discovery and development of novel biologic therapeutics aimed at addressing immune-inflammatory conditions, including rheumatoid arthritis, metabolic diseases, fibrosis, and nonalcoholic steatohepatitis. Bird Rock Bio's technology focuses on creating highly selective monoclonal antibodies targeting specific members of the G-protein coupled receptor (GPCR) family, a class of proteins critical for therapeutic efficacy. Its lead product, RYI-008, is a potent monoclonal antibody targeting IL-6, a cytokine linked to inflammation and cancer. The company is dedicated to meeting the medical needs of patients in China while also aiming for global impact. Bird Rock Bio has a growing pipeline of therapeutic antibodies developed through proprietary technologies that ensure specificity and effectiveness in treatment.

Anaphore (formerly ImmunoNewCo) is developing a new class of protein therapeutics to address significant unmet medical needs for patients with serious or life-threatening diseases.

Serentis develops medical products and drugs. Its products include SRD441, a novel compound that targets endogenous pro-inflammatory and staphylococcus aureus-derived proteases; and SRD174, a topical product designed to produce relief of pruritus. The company’s research programs include SRD326, a topically-applied product for relief from symptoms of Raynaud’s phenomenon; and SRD285 which provides an approach to wound care, promoting enhanced wound healing and local analgesia. Serentis was founded in 2006 and is based in Cambridge, United Kingdom.

Serentis develops medical products and drugs. Its products include SRD441, a novel compound that targets endogenous pro-inflammatory and staphylococcus aureus-derived proteases; and SRD174, a topical product designed to produce relief of pruritus. The company’s research programs include SRD326, a topically-applied product for relief from symptoms of Raynaud’s phenomenon; and SRD285 which provides an approach to wound care, promoting enhanced wound healing and local analgesia. Serentis was founded in 2006 and is based in Cambridge, United Kingdom.

PharmaKodex is a pharmaceutical company that develops and commercializes small molecule drugs for treating pain and neurological conditions. The company was founded in 2006 and is based in Cambridge, the United Kingdom with an additional office in Chippenham, the United Kingdom. As of February 23, 2009, PharmaKodex Ltd. operates as a subsidiary of Orexo AB.

Ambrx, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the development of engineered precision biologics through an expanded genetic code technology platform. This innovative approach enables the incorporation of synthetic amino acids into proteins, facilitating the creation of next-generation therapeutics. Ambrx focuses on various product candidates, including antibody drug conjugates (ADCs), bispecific antibodies, targeted immuno-oncology treatments, and long-acting therapeutic peptides aimed at addressing metabolic and cardiovascular diseases. The company has a robust development pipeline featuring multiple clinical and preclinical programs, with its lead candidate ARX788 among them. Ambrx also collaborates with other organizations, such as MabSpace Biosciences and BeiGene, to enhance its research and development efforts in oncology and other therapeutic areas. Founded in 2003, Ambrx is committed to advancing the efficacy and safety of new biologic therapies for patients.